Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MELT-400
- Development stage
- Preclinical
- Lead developer
- Harrow
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
MELT-400 is a sublingual, non-opioid formulation of ketamine developed by Melt Pharmaceuticals for pain management. It utilizes Catalent's proprietary Zydis® orally disintegrating tablet (ODT) technology to provide a needle-free, sublingual delivery system. MELT-400 is also a component of MELT-300, a combination product of midazolam and ketamine. Melt Pharmaceuticals submitted an Investigational New Drug (IND) application for MELT-400 to the FDA in early 2022.
- Other names
- MELT-400MELT400MELT 400
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on MELT-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MELT-400.